Author name: Praharsh Gour

Let’s IPsa Loquitur: a Quick Rundown of the Major IP Developments from 2025

/ By / Trademark

In the latest episode of Let’s IPsa Loquitur, I sat down with Sonisha, Tanishka, Kartikeya, Kartik, Ambika, Malobika, and Bharathwaj for a quick rundown of the major IP developments from 2025. In Part 1 of this three-part discussion, we go over the key Trademark Developments, featuring orders that made headlines and stood out for their jurisprudential rigour. We also discuss important policy-related developments, along with other updates that do not fall within these categories. Readers can check it out below:- […]

Let’s IPsa Loquitur: a Quick Rundown of the Major IP Developments from 2025 Read More »

[SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz

/ By / Patent, Trademark

Yesterday, Khushi and I wrote on the Semaglutide patent expiry and what it could mean for Indian generic companies and the general public. And while the market is seeing more affordable versions of the drug, a separate story is taking place in the Delhi High Court with Novo Nordisk filing a fresh set of trademark and patent infringement suits against generic companies.  The Ozempic Name Game: Novo Nordisk v. DRL Round 2 On Semaglutide injections, Novo Nordisk has filed a

[SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz Read More »

Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India

/ By / Patent

[This post is co-authored with Khushi Krishania. Khushi is a third-year B.Sc. LL.B. (Hons.) {Cybersecurity} student at the National Law Institute University, Bhopal, with a particular interest in the intersection of copyright and data protection law.] Christmas came early for Indian generic manufacturers as the Indian patent on Semaglutide, a potent GLP-1 receptor agonist, expired on March 20. The drug is commercially sold by Novo Nordisk as Ozempic and Wegovy and is used to manage type-2 diabetes and obesity. After

Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India Read More »

Supreme Court Refuses to Interfere in the Risdiplam Case, Rejects Roche’s SLP 

/ By / Patent

In our previous post on the Risdiplam saga, we had mentioned that Roche has filed an SLP before the Supreme Court. Earlier today, the SC dismissed this SLP with instructions to the High Court that it shall endeavour to dispose of the suit expeditiously. Roche raised the usual arguments on rare diseases, that very few companies invest in them, and that they came up with this drug after a lot of research. And stated that they were able to come

Supreme Court Refuses to Interfere in the Risdiplam Case, Rejects Roche’s SLP  Read More »

Breaking: DHC Dismisses Roche’s Appeal in the Risdiplam Case

/ By / Patent

In a huge development concerning the Risdiplam litigation saga, a division bench of the Delhi High Court has rejected the appeal against the order refusing to grant an interim injunction to Roche. Pronounced just a few mins ago, in the decision, J. Hari Shankar (for the bench) said that a credible challenge has been made on grounds listed in Section 64 (1)(f) against Roche’s patent and thus refused to interfere with the Single judge’s judgement. For the uninitiated, Section 64(1)(f)

Breaking: DHC Dismisses Roche’s Appeal in the Risdiplam Case Read More »

Taking a Look at the Patent Provisions from the India-UK CETA: Does it Set a Course for Future Trade Negotiations for India?

/ By / Patent

Two months after showing up in the news, the text of the India-UK Comprehensive Economic and Trade Agreement (CETA) was signed and published on July 24. The Agreement is being touted as a “Historic” and “Landmark” trade deal, which is supposed to give unprecedented market access to Indian goods in the UK. This comes at an interesting time, in the midst of ongoing India-US trade agreement talks, which are being conducted under the looming threat of August 1 reciprocal tariff

Taking a Look at the Patent Provisions from the India-UK CETA: Does it Set a Course for Future Trade Negotiations for India? Read More »

Supreme Court to Hear Patent Officers Association’s Challenge to Dr. Unnat P. Pandit’s Appointment as the Controller General

/ By / Others

The heated battle between the incumbent Controller General of Patents Designs and Trademarks and the All India Patent Officers’ Welfare Association (AIPOWA) reached the doorsteps of the Supreme Court this summer in the form of a special leave petition. The petition stems from the Delhi High Court’s refusal (pdf) to entertain AIPOWA’s writ challenging the appointment of the incumbent Controller General- Dr. Unnat P Pandit. The association challenged the appointment of Dr. Pandit, alleging him to be ineligible for the

Supreme Court to Hear Patent Officers Association’s Challenge to Dr. Unnat P. Pandit’s Appointment as the Controller General Read More »

Whirlwind of Changes Expected in India’s Patent, Copyright, and GI Regimes as India and the UK Finally Finalize the FTA 

/ By / Copyright, Others, Patent

Running a few years behind the initial 2022 Diwali deadline, India and the UK have finally concluded their talks on the Free Trade Agreement (FTA). Projected as an “ambitious and mutually beneficial” FTA, the agreement marks a significant step for both economies. Reportedly, this is the UK’s biggest trade deal since Brexit and on the Indian side, it shifts the focus from east to west, in terms of bilateral trade partnerships, and saw India negotiating on many non-trade issues like

Whirlwind of Changes Expected in India’s Patent, Copyright, and GI Regimes as India and the UK Finally Finalize the FTA  Read More »

Comments Invited for Draft Guidelines on Similar Biologics

/ By / Drug Regulation

On May 6, the Central Drug Standard Control Organization published the draft version of the Revised Guidelines on Similar Biologics, inviting comments from the concerned stakeholders. These guidelines were prepared after a Committee composed of technical subject experts, representatives from the National Institute of Biologics, Dept. of Biotechnology, and representatives from industries manufacturing similar biologics. As explained in the introductory pages, the guidelines are revised in light of advances in scientific knowledge and to update the existing guidelines in light

Comments Invited for Draft Guidelines on Similar Biologics Read More »

Plagiarism and PMLA: Taking a look at the ED’s involvement in the Shankar- Tamilnandan “Enthiran” Copyright Saga

/ By / Copyright

[This post has been co-authored with Anjali Tripathi. Anjali is a fourth-year law student at JGLS with an interest in IP rights, access to education, and the creative arts. Her previous post can be accessed here.] In a big relief to movie director Shankar, the Madras High Court today stayed the Enforcement Directorate (ED)’s decision to provisionally attach his assets worth ₹10.11 crore under the Prevention of Money Laundering Act (“PMLA”), 2002. On February 20, the ED released a press

Plagiarism and PMLA: Taking a look at the ED’s involvement in the Shankar- Tamilnandan “Enthiran” Copyright Saga Read More »

Scroll to Top